Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 14, 2018 | June 15, 2018 |
| EXACT SCIENCES CORPEXAS · Entity 56619 | Director | February 26, 2021 | March 02, 2021 |
| Invivyd, Inc.IVVD · Entity 721 | Director | May 23, 2023 | May 25, 2023 |
| Mereo BioPharma Group plcMREO · Entity 7264 | Director | February 26, 2026 | February 27, 2026 |
| OncoMed Pharmaceuticals IncOMED · Entity 158190 | Director | June 22, 2018 | June 25, 2018 |
| Tvardi Therapeutics, Inc.TVRD · Entity 7579 | Director | June 09, 2026 | June 11, 2026 |
| X4 Pharmaceuticals, IncXFOR · Entity 5638 | Director | January 01, 2026 | January 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Akebia Therapeutics, Inc.
Report date June 14, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.14 · Expires 2028-06-14 | Direct | 12,500 |
Reported balance
After 2018-06-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-14 · Grant · Acquired 12,500 · Balance 12,500 F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents an option to purchase shares of Akebia Therapeutics, Inc.'s (the "Company's") common stock granted by the Company pursuant to the Company's 2014 Incentive Plan (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Company.
EXACT SCIENCES CORP
Report date February 26, 2021 · Filed March 02, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,558 |
Ending reported balance
After 2021-02-26 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-02-26 · Exercise / conversion · Acquired 10,108 · Balance 21,579 F1: Represents shares of common stock received upon exercise of a stock option award. Row 2 · 2021-02-26 · Sale · Disposed 19,021 · Balance 2,558 F2: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.98 | Direct | 0 |
Reported balance
After 2021-02-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-02-26 · Exercise / conversion · Disposed 10,108 · Balance 0 F3: These options vested and became exercisable on February 9, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received upon exercise of a stock option award.
F2: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan.
F3: These options vested and became exercisable on February 9, 2016.
Invivyd, Inc.
Report date May 23, 2023 · Filed May 25, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.70 · Expires 2033-05-22 | Direct | 50,000 |
Reported balance
After 2023-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-23 · Grant · Acquired 50,000 · Balance 50,000 F1: This option was granted on May 23, 2023 and vests in full upon the earlier of (i) May 23, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on May 23, 2023 and vests in full upon the earlier of (i) May 23, 2024 or (ii) the date of the Issuer's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date.
Mereo BioPharma Group plc
Report date February 26, 2026 · Filed February 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Share Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2036-02-26 | Direct | 66,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 66,000 · Balance 66,000 F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date. F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests in substantially equal monthly installments over a one year period from the February 26, 2026 grant date.
F2: Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer.
OncoMed Pharmaceuticals Inc
Report date June 22, 2018 · Filed June 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2028-06-22 | Direct | 15,000 |
Reported balance
After 2018-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-22 · Grant · Acquired 15,000 · Balance 15,000 F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.
Tvardi Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2036-06-08 | Direct | 6,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 6,000 · Balance 6,000 F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
X4 Pharmaceuticals, Inc
Report date January 01, 2026 · Filed January 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2036-01-01 | Direct | 0 |
Reported balance
After 2026-01-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-01 · Grant · Acquired 110,000 · Balance 0 F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option shall vest in full upon stockholder approval of an increase in the share reserve under the Companys Amended and Restated 2017 Equity Incentive Plan at the Companys 2026 annual meeting of stockholders, subject to the Reporting Person continuing to provide services through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
LogicBio Therapeutics, Inc.
Report date November 16, 2022 · Filed November 18, 2022
Section 16 reporting ended · disclosed 2022-11-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 1
1 source rowRow 1 · 2022-11-16 · Disposition to issuer · Disposed 3,141 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.38 · Expires 2032-06-17 | Direct | 0 |
Reported balance
After 2022-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-11-16 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022. F2: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 3, 2022 (the "Merger Agreement"), by and among LogicBio Therapeutics, Inc. (the "Company"), Alexion Pharmaceuticals, Inc. ("Parent") and Camelot Merger Sub, Inc. ("Merger Sub"), on November 16, 2022 (the "Effective Time"), Merger Sub merged with and into the Company (the "Merger"), with the Company continuing as the surviving corporation in the Merger and as a wholly-owned subsidiary of Parent, and, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company was cancelled and converted into the right to receive $2.07 in cash, without interest, less any applicable withholding taxes.
F2: The options were granted on June 17, 2022. The options were scheduled to vest in full on the earlier of (i) the first anniversary of the grant date, and (ii) the day prior to the Company's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Company on the vesting date.
F3: At the Effective Time, each option was cancelled pursuant to the terms of the Merger Agreement; provided, that each option with a per share exercise price equal to or greater than $2.07 was automatically cancelled for no consideration. For more information see the Solicitation/Recommendation Statement on Schedule 14D-9 filed by the Company with the United States Securities and Exchange Commission on October 18, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2017 Filed Jun 19, 2017 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 12,500 | $0.00 Strike: $14.37 | $0.00 |
DisclosureSEC source: 0001562180-17-002290 · primarydocument.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-15 F1 · derivative.exercise_date: 100% of the option shares vest on the first anniversary of the date of grant (the "Vesting Date"), provided that the Reporting Person remains in continuous service as a member of the Issuer's Board of Directors through the Vesting Date, and provided further that the options held by the Reporting Person shall be eligible for vesting acceleration upon a "Change in Control" as defined and provided for in the Issuer's Non-Employee Director Stock Option Award Agreement. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 16:54 UTC | OncoMed Pharmaceuticals Inc OMED · Entity 158190 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0001140361-17-023613 · doc1.xml · derivative · entry 1 WYZGA MICHAEL S · CIK 0001201256 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: The option vests as to 100% of the shares subject thereto upon the earlier of one year following the grant date or the date of the subsequent year's annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.